REGN7075 in Combination With Cemiplimab in Adult Participants With Advanced Solid Tumors (COMBINE-EGFR-1)

  • STATUS
    Recruiting
  • End date
    Apr 3, 2025
  • participants needed
    402
  • sponsor
    Regeneron Pharmaceuticals
Updated on 21 July 2022

Summary

The primary objective of the study is:

Dose Escalation:

• To assess the safety and tolerability of a REGN7075 monotherapy lead-in and REGN7075 in combination with cemiplimab in patients with advanced solid tumors

Dose Expansion:

• To assess the preliminary efficacy of REGN7075 in combination with cemiplimab within selected advanced solid tumor-specific cohorts, as measured by objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) and/or composite response criteria

The secondary objectives of the study are:

Dose Escalation:

  • To characterize the pharmacokinetics (PK) of REGN7075 alone and in combination with cemiplimab
  • To assess the preliminary efficacy of REGN7075 in combination with cemiplimab, as measured by ORR, overall survival (OS), progression free survival (PFS), duration of response (DOR), complete response (CR) rate, and disease control rate (DCR) per RECIST 1.1 and/or composite response criteria
  • To assess immunogenicity of REGN7075 and cemiplimab

Dose Expansion:

  • To assess the preliminary efficacy of REGN7075 in combination with cemiplimab within selected advanced solid tumor-specific cohorts of patients as measured by OS, PFS, DOR, CR rate, and DCR per RECIST 1.1 and/or composite response criteria
  • To assess the safety and tolerability of REGN7075 in combination with cemiplimab
  • To characterize the PK of REGN7075 alone and in combination with cemiplimab
  • To assess immunogenicity to REGN7075 and cemiplimab

Details
Condition Advanced Solid Tumors
Treatment Cemiplimab, REGN7075
Clinical Study IdentifierNCT04626635
SponsorRegeneron Pharmaceuticals
Last Modified on21 July 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

≥18 years of age (≥20 years of age for patients enrolled in Japan)
Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Has histologically or cytologically confirmed cancer that meets criteria as defined in the protocol
Expansion Cohorts only: Is anti-programmed cell death protein-1 (PD-1)/programmed cell death ligand-1 (PD-L1) naïve, defined as never having previously been treated with a drug that targets the PD-1
Has at least 1 lesion that meets study criteria as defined in the protocol
Willing to provide tumor tissue from newly obtained biopsy (at a minimum core biopsy) from a tumor site that has not been previously irradiated
Has adequate organ and bone marrow function as defined in the protocol
In the judgement of the investigator, has a life expectancy of at least 3 months

Exclusion Criteria

Is currently participating in another study of a therapeutic agent
Has participated in any study of an investigational agent or an investigational device within 4 weeks of the first administration of study drug as defined in the protocol
Has received treatment with an approved systemic therapy within 4 weeks of the first administration of study drug or has not yet recovered (ie, grade 1 or baseline) from any acute toxicities
Has received recent anti-epidermal growth factor receptor (EGFR) antibody therapy as defined in the protocol
Has received radiation therapy or major surgery within 14 days of the first administration of study drug or has not recovered (ie, grade 1 or baseline) from adverse events
Has received any previous systemic, non-immunomodulatory biologic therapy within 4 weeks of first administration of study drug
Has had prior anti-cancer immunotherapy within 5 half-lives prior to study drug as defined in the protocol
Has second malignancy that is progressing or requires active treatment as defined in the protocol
Has any condition requiring ongoing/continuous corticosteroid therapy (>10 mg prednisone/day or anti-inflammatory equivalent) within 1-2 weeks prior to the first dose of study drug as defined in the protocol
Has ongoing or recent (within 5 years) evidence of significant autoimmune disease or any other condition that required treatment with systemic immunosuppressive treatments as defined in the protocol
Has untreated or active primary brain tumor, CNS metastases, leptomeningeal disease, or spinal cord compression
Has encephalitis, meningitis, organic brain disease (eg, Parkinson's disease) or uncontrolled seizures within 1 year prior to the first dose of study drug
Has any ongoing inflammatory skin disease as defined in the protocol NOTE: Other protocol-defined Inclusion/ Exclusion Criteria apply
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note